187 related articles for article (PubMed ID: 28991928)
21. A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus.
Ruszkowska-Ciastek B; Sokup A; Socha MW; Ruprecht Z; Hałas L; Góralczyk B; Góralczyk K; Gadomska G; Rość D
J Zhejiang Univ Sci B; 2014 Jun; 15(6):575-81. PubMed ID: 24903995
[TBL] [Abstract][Full Text] [Related]
22. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
Kopparapu PK; Boorjian SA; Robinson BD; Downes M; Gudas LJ; Mongan NP; Persson JL
Anticancer Res; 2013 Jun; 33(6):2381-90. PubMed ID: 23749886
[TBL] [Abstract][Full Text] [Related]
23. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
Fine BA; Valente PT; Feinstein GI; Dey T
Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
[TBL] [Abstract][Full Text] [Related]
24. Analysis of circulating vascular endothelial growth factor and its soluble receptors in patients with different forms of chronic urticaria.
Jagodzinska J; Polaniak R; Birkner E; Kasperska-Zajac A
Biomed Res Int; 2015; 2015():578383. PubMed ID: 25756047
[TBL] [Abstract][Full Text] [Related]
25. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
[TBL] [Abstract][Full Text] [Related]
26. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer.
Bünger S; Haug U; Kelly FM; Klempt-Giessing K; Cartwright A; Posorski N; Dibbelt L; Fitzgerald SP; Bruch HP; Roblick UJ; von Eggeling F; Brenner H; Habermann JK;
J Biomol Screen; 2011 Oct; 16(9):1018-26. PubMed ID: 21807963
[TBL] [Abstract][Full Text] [Related]
27. Angiogenic factors in blood serum of bone tumor patients.
Babkina IV; Kuznetsov IN; Soloviev YN; Russo EY; Ten EA
Klin Lab Diagn; 2013 Oct; (10):63-5, 31-3. PubMed ID: 24640099
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma.
Nikolaou M; Kourea HP; Tzelepi V; Adonakis G; Scopa CD; Tsapanos V; Kardamakis D; Kalofonos C; Decavalas G
J BUON; 2014; 19(1):198-202. PubMed ID: 24659664
[TBL] [Abstract][Full Text] [Related]
29. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
Ivanov I
Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.
Coulon S; Francque S; Colle I; Verrijken A; Blomme B; Heindryckx F; De Munter S; Prawitt J; Caron S; Staels B; Van Vlierberghe H; Van Gaal L; Geerts A
Cytokine; 2012 Aug; 59(2):442-9. PubMed ID: 22658783
[TBL] [Abstract][Full Text] [Related]
31. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
Hefler LA; Zeillinger R; Grimm C; Sood AK; Cheng WF; Gadducci A; Tempfer CB; Reinthaller A
Gynecol Oncol; 2006 Nov; 103(2):512-7. PubMed ID: 16750560
[TBL] [Abstract][Full Text] [Related]
32. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
33. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Wieczór R; Gadomska G; Ruszkowska-Ciastek B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
J Zhejiang Univ Sci B; 2015 Nov; 16(11):948-56. PubMed ID: 26537213
[TBL] [Abstract][Full Text] [Related]
34. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
Wieczór R; Wieczór AM; Gadomska G; Stankowska K; Fabisiak J; Suppan K; Pulkowski G; Budzyński J; Rość D
J Zhejiang Univ Sci B; 2016 Nov.; 17(11):842-849. PubMed ID: 27819131
[TBL] [Abstract][Full Text] [Related]
35. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.
Saarelainen SK; Staff S; Peltonen N; Lehtimäki T; Isola J; Kujala PM; Vuento MH; Mäenpää JU
Tumour Biol; 2014 May; 35(5):4651-7. PubMed ID: 24420153
[TBL] [Abstract][Full Text] [Related]
36. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
[TBL] [Abstract][Full Text] [Related]
37. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
Jaroszewicz J; Januszkiewicz M; Flisiak R; Rogalska M; Kalinowska A; Wierzbicka I
Cytokine; 2008 Oct; 44(1):14-7. PubMed ID: 18656381
[TBL] [Abstract][Full Text] [Related]
38. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
39. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract][Full Text] [Related]
40. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
